Weiwei Chen

Dr. Weiwei Chen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020
Verified
Journal Article
Closed access
WCW. -W. Chen
W. -W. Chen
JQJ. -W. Qi
J. -W. Qi
YHY. Hang
Y. Hang
JWJ. -X. Wu
J. -X. Wu
XZX. -X. Zhou
X. -X. Zhou
WCWeiwei Chen
Weiwei Chen

6 January 2023 in Cancer Genetics
Verified
Journal Article
Open access
WCWeiwei Chen
Weiwei Chen
DNDaguang Ni
Daguang Ni
HZHailin Zhang
Hailin Zhang
XLxia Li
xia Li
YJYouqin Jiang
Youqin Jiang
WSWenyu Shi
Wenyu Shi
Aberrant ubiquitin modifications caused by an imbalance in the activities of ubiquitinases and de-ubiquitinases are emerging as important mechanisms underlying non-small cell lung cancer (NSCLC) progression. The deubiquitinating enzyme ubiquitin-specific peptidase 15 (USP15) has been identified as an important factor in oncogenesis and a potential therapeutic target. However, the expression profile and function of USP15 in NSCLC remain elusive. In the present study, we investigated the expression pattern and the potential biological functions of USP15 in NSCLC both in cells and animal models. Our data revealed that USP15 was highly expressed in NSCLC tissues and cells compared with normal counterpart. We subsequently knocked down USP15 expression in two NSCLC cell lines, which significantly suppressed cell proliferation. In addition, knocking down USP15 expression reduced NSCLC cell migration and invasion according to the results from Matrigel-Transwell analysis. NSCLC animal model results showed that USP15 knockdown also reduced NSCLC size. Biochemical analysis revealed that USP15 knockdown inhibited matrix metalloproteinase (MMP)3 and MMP9 expression. Furthermore, high levels of USP15 and MMP3 expression were associated with poor prognosis in NSCLC. In conclusion, the results from the present study suggest that the high expression of USP15 promotes NSCLC tumorigenesis. Therefore, it is proposed that USP15 and MMPs may represent novel biomarkers for NSCLC progression and prognosis.

2 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XZXiaofei Zhang
Xiaofei Zhang
DADashan Ai
Dashan Ai
JWJuanqi Wang
Juanqi Wang
YCYun Chen
Yun Chen
QLQi Liu
Qi Liu
KZKuaile Zhao
Kuaile Zhao
Background: This trial aims to explore the feasibility and safety of postoperative radiotherapy covering all regional lymph node areas for locally advanced thoracic esophageal squamous cell carcinoma patients treated with intensity-modulated radiation therapy (IMRT). Methods: This was a single-center single-arm, phase II clinical trial initiated in 2014. Patients who were treated with radical transthoracic resection and had negative margins within 3 months and histologically confirmed esophageal squamous cell carcinoma (pT3-4 or N+, M0 determined by the 7th edition of the AJCC guidelines) were recruited in this trial. Postoperative radiotherapy was performed with a total dose of 40 Gy in 20 fractions using IMRT. Clinical target volumes (CTVs) included the tumor bed, anastomosis, bilateral supraclavicular region, mediastinal lymph nodes, left gastric lymph nodes and celiac trunk lymph nodes. The primary endpoint was the 2-year local control rate, and the secondary endpoints were overall survival (OS) and adverse events (AEs). Results: A total of 70 eligible patients were recruited from 2014 to 2016. The 2-year local control rate, as the primary endpoint, was 67.3%. In addition, the median OS was 57.0 months, with 1-year and 3-year OS rates of 92.8% and 60.9%, respectively. Among the patients, 28/40 (40%) developed locoregional recurrence, with 25.7% involving hematogenous recurrences. All reported AEs occurred during the course of IMRT or within 6 months thereafter. None of them suffered grade 4 hematological or nonhematological AEs. Nearly all patients completed the entire course of postoperative radiotherapy, with a completion rate of 97.1%. Conclusion: For an extensive target volume, 40 Gy is feasible and shows acceptable toxicity in patients with locally advanced thoracic esophageal squamous cell carcinoma, although the local recurrence rate is relatively high. Our findings provide a basis for further exploration of high-dose radiation with extensive CTV combined with chemotherapy. Clinical Trial Registration: [http://www.clinicaltrials.gov/ct2/results?cond=&term=NCT02384811&cntry=&state=&city=&dist=], identifier [NCT02384811].

1 April 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
JDJiaying Deng
Jiaying Deng
YXYi Xia
Yi Xia
YCYun Chen
Yun Chen
QLQi Liu
Qi Liu
WCWeiwei Chen
Weiwei Chen
KZKuaile Zhao
Kuaile Zhao
Background: Radiotherapy plays an important role in multidisciplinary treatment of esophageal squamous cell carcinoma (ESCC). However, the long term prognosis, relapse and metastasis of patients who received radiotherapy with different radiotherapy technique and fractions were unclear. The objective of the present study was to investigate the correlation of them. Methods: Six prospective studies were conducted in succession including 475 locally advanced ESCC patients received two-dimensional (2D) and three-dimensional (3D) radiotherapy with late course accelerated hyperfractionated fraction (LCAF) and continuous accelerated hyperfractionated fraction (CAHF). Overall survival was analyzed using the Kaplan-Meier method. Research regarding the incidence of Grade 3 or higher acute radiation-related toxicity was conducted. Details of relapse and metastasis were also investigated. Results: The median follow-up time was 57.5 months. The overall incidence of failure was 49%. No significant survival difference was observed in both LACF vs. CAHF and 2DRT vs. 3DRT groups (P=0.55 and 0.64, respectively). Fewer incidences of acute toxicities were observed in ESCC patients treated with 3DRT compared with those treated with 2DRT (P<0.01). Fewer acute radiation esophagitis was observed in LCAF comparison of CAHF (P<0.01), however no significant difference of acute radiation pneumonitis was observed. A total of 65 patients were considered to have metastatic disease affecting distant organs: lung (n=39, 8.2%), liver (n=35, 7.4%) and bone (n=21, 4.4%). Conclusions: About half of patients suffered local/regional failure following radiotherapy. 3DRT reduced acute radiotherapy toxicities compared with 2DRT. LCAF was more tolerant than CAHF.